Literature DB >> 20412532

The utility of patient characteristics in predicting severe ADAMTS13 deficiency and response to plasma exchange.

Melissa J Bentley1, Chris M Lehman, Robert C Blaylock, Andrew R Wilson, George M Rodgers.   

Abstract

BACKGROUND: Idiopathic thrombotic thrombocytopenic purpura (TTP) is a rare form of thrombotic microangiopathy (TMA) characterized by extreme deficiency of ADAMTS13, an enzyme responsible for cleavage of von Willebrand factor. Plasma exchange therapy is the cornerstone of current treatment and is ineffective for most other forms of TMA. The availability of ADAMTS13 testing has improved diagnostic accuracy and appropriate selection of patients who are most likely to respond to plasma exchange. STUDY DESIGN AND METHODS: We performed a retrospective chart review of 110 cases of clinically suspected TTP with ADAMTS13 test results from 2005 to the present. The primary goal was to identify presenting clinical and/or laboratory features of patients with ADAMTS13 deficiency that would prove useful in increasing the likelihood of, or excluding the possibility of, TTP. In addition, patient outcomes including alternative diagnoses and response to plasma exchange were reviewed.
RESULTS: Significant correlations for severe ADAMTS13 deficiency were seen for four of the observed variables: indirect bilirubin, reticulocyte percentage, creatinine, and platelet count; a fifth variable, D-dimer, just missed significance but performed well in subsequent analysis. Receiver operator characteristics curves for individual variables had area under the curve (AUC) values ranging from 0.75 to 0.85; a combined model had an AUC of 0.98. In addition, we constructed tree models both for clinical use as a diagnostic algorithm and for recursive partitioning to help establish cutoff points for categorical variables in developing an easy-to-use clinical prediction score.
CONCLUSION: These results may enable the rapid exclusion and accurate diagnosis of TTP using readily available laboratory data.
© 2010 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20412532     DOI: 10.1111/j.1537-2995.2010.02653.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

Review 1.  Clinical and laboratory diagnosis of TTP: an integrated approach.

Authors:  Thita Chiasakul; Adam Cuker
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Response to "Predictors of survival in thrombotic thrombocytopenic purpura" Haematologica 2013;98(5):e58.

Authors:  Paul Coppo
Journal:  Haematologica       Date:  2013-07       Impact factor: 9.941

3.  Application of PLASMIC Score in Risk Prediction of Thrombotic Thrombocytopenic Purpura: Real-World Experience From a Tertiary Medical Center in Taiwan.

Authors:  Chun-Hui Lee; Yi-Ching Huang; Sin-Syue Li; Ya-Ting Hsu; Ya-Ping Chen; Tsai-Yun Chen
Journal:  Front Med (Lausanne)       Date:  2022-05-09

Review 4.  Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children.

Authors:  Cecile L Karsenty; Susan E Kirk; Hannah L Helber; Jose M Esquilin; Jenny M Despotovic; Amanda B Grimes
Journal:  Front Immunol       Date:  2022-04-11       Impact factor: 8.786

5.  Expert statement on the ICU management of patients with thrombotic thrombocytopenic purpura.

Authors:  Elie Azoulay; Philippe R Bauer; Eric Mariotte; Lene Russell; Paul Knoebl; Ignacio Martin-Loeches; Frédéric Pène; Kathryn Puxty; Pedro Povoa; Andreas Barratt-Due; Jose Garnacho-Montero; Julia Wendon; Laveena Munshi; Dominique Benoit; Michael von Bergwelt-Baildon; Marco Maggiorini; Paul Coppo; Spero Cataland; Agnès Veyradier; Andry Van de Louw
Journal:  Intensive Care Med       Date:  2019-10-07       Impact factor: 17.440

6.  Comparison of Clinical Scoring Systems in the Management of Patients with Microangiopathic Hemolytic Anemia and Thrombocytopenia

Authors:  Mehmet Baysal; Elif Ümit; Hakkı Onur Kırkızlar; Ahmet Muzaffer Demir
Journal:  Turk J Haematol       Date:  2020-11-09       Impact factor: 1.831

Review 7.  TTP: From empiricism for an enigmatic disease to targeted molecular therapies.

Authors:  Nuno A G Graça; Bérangère S Joly; Jan Voorberg; Karen Vanhoorelbeke; Nicolas Béranger; Agnès Veyradier; Paul Coppo
Journal:  Br J Haematol       Date:  2022-02-10       Impact factor: 8.615

8.  Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature.

Authors:  Giuseppe Viscardi; Nicoletta Zanaletti; Maria Giovanna Ferrara; Antonello Sica; Umberto Falcone; Salvatore Guastafierro; Umberto Bracale; Dario Ribero; Morena Fasano; Stefania Napolitano; Pasquale Vitale; Vincenzo De Falco; Emilio Francesco Giunta; Erika Martinelli; Davide Ciardiello; Fortunato Ciardiello; Teresa Troiani
Journal:  ESMO Open       Date:  2019-09-19

Review 9.  Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review.

Authors:  Adrien Joseph; Aurélie Cointe; Patricia Mariani Kurkdjian; Cédric Rafat; Alexandre Hertig
Journal:  Toxins (Basel)       Date:  2020-01-21       Impact factor: 4.546

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.